Classification of the Crystallization Behavior of Amorphous Active Pharmaceutical Ingredients in Aqueous Environments
- 2k Downloads
To classify the crystallization behavior of amorphous active pharmaceutical ingredients (API) exposed to aqueous environments.
A set of approximately 50 chemically and physically diverse active pharmaceutical ingredients (APIs) was selected for this study. Two experimental setups were employed to characterize the crystallization behavior of the amorphous API in an aqueous environment. For the first approach, precipitation, as evidenced by the development of turbidity, was induced using the solvent shift method, by mixing concentrated API solutions in DMSO with an aqueous buffer in a capillary. Subsequently, crystallization was monitored in situ over time using synchrotron radiation (simultaneous SAXS/WAXS beamline 12-ID-B at the Advanced Photon Source, Argonne National Laboratories, Argonne, IL). In the second approach, amorphous films were prepared by melt quenching; after adding buffer, crystallization was monitored with time using polarized light microscopy.
In general, the crystallization behavior of a given compound was similar irrespective of the experimental method employed. However, the crystallization behavior among different compounds varied significantly, ranging from immediate and complete crystallization to no observable crystallization over biorelevant time scales. Comparison of the observed behavior with previous studies of crystallization tendency in non-aqueous environments revealed that the crystallization tendency of individual APIs was somewhat similar regardless of the crystallization environment.
API properties, rather than the method by which amorphous materials are generated, tend to dictate crystallization behavior in aqueous media.
KEY WORDSactive pharmaceutical ingredient amorphous crystallization polarized light microscopy synchrotron radiation
- 9.Murdande SB, Pikal MJ, Shanker RM, Bogner RH. Solubility advantage of amorphous pharmaceuticals: II. Application of quantitative thermodynamic relationships for prediction of solubility enhancement in structurally diverse insoluble pharmaceuticals. Pharm Res. 2010;27(12):2704–14.CrossRefPubMedGoogle Scholar
- 11.Hsieh YL, Ilevbare GA, Van Eerdenbrugh B, Box KJ, Sanchez-Felix MV, Taylor LS. pH-Induced precipitation behavior of weakly basic compounds: determination of extent and duration of supersaturation using potentiometric titration and correlation to solid state properties. Pharm Res. 2012;29(10):2738–53.CrossRefPubMedGoogle Scholar
- 28.Krc J. Crystallographic properties of flufenamic acid. Microscope. 1977;25(1):31–45.Google Scholar
- 29.McConnell JF. 3′-Trifluoromethyldiphenylamine-2-carboxylic acid, C14H10F3NO2 flufenamic acid. Cryst Struct Commun. 1973;2:459–61.Google Scholar
- 33.Mullin JW. Crystallization. 4th ed. Oxford: Elsiever Butterworth-Heinemann; 2001.Google Scholar